beta
Trial Radar AI
Clinical Trial NCT06787560 for Bone Marrow Failure Syndrome is recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One study matched filter criteria
Card View
Back to Search

CD7 CAR-T Cell Sequential Allo-HSCT for Non-malignant Blood and Immune System Diseases Early Phase 1 20

Recruiting
Clinical Trial NCT06787560 is designed to study Treatment for Bone Marrow Failure Syndrome. It is a Early Phase 1 interventional study that is recruiting, having started on January 31, 2025, with plans to enroll 20 participants. Led by Zhejiang University, it is expected to complete by January 31, 2028. The latest data from ClinicalTrials.gov was last updated on January 22, 2025.
Brief Summary
A Clinical Study on the Safety and Effectiveness of CD7 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell Transplantation for Non-malignant Blood and Immune System Diseases
Detailed Description
This is a single-arm, open-label clinical trial to evaluate the safety and efficacy of CD7 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell Transplantation for Non-malignant Blood and Immune System Diseases. It is planned to enroll 12-20 participants in this trial.
Official Title

Clinical Study on the Safety and Efficacy of CD7 CAR-T Cell Sequential Allogeneic Hematopoietic Stem Cell Transplantation for Non-malignant Blood and Immune System Diseases

Conditions
Bone Marrow Failure Syndrome
Other Study IDs
  • TXB2024023
NCT ID Number
NCT06787560
Start Date (Actual)
2025-01-31
Last Update Posted
2025-01-22
Completion Date (Estimated)
2028-01-31
Enrollment (Estimated)
20
Study Type
Interventional
PHASE
Early Phase 1
Status
Recruiting
Keywords
CAR-T
Allo-HSCT
Immuno Deficiency Disorders
Primary Purpose
Treatment
Design Allocation
N/A
Interventional Model
Single Group
Masking
None (Open Label)
Arms / Interventions
Participant Group/ArmIntervention/Treatment
ExperimentalCD7 CAR-T cells（ CD7 chimeric antigen receptor T cells）
Patients or donors undergo leukapheresis. Patients will receive a lymphodepletion chemotherapy with CTX、Flu、VP-16 before CAR-T cells infusion. CAR-T cells could be transfused after 48 hours of preconditioning.
CD7 CAR-T cells injection
Each subject receive CD7 CAR T-cells by intravenous infusion
Allo-HSCT
allogeneic hematopoietic stem cell transplantation
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Incidence of treatment-emergent adverse events (TEAEs)
Incidence of treatment-emergent adverse events
Up to 2 years after Treatment
Transplant related mortality rate
The proportion of patients who died after transplantation to the total number of transplant patients during the same period
Up to 100 days after Treatment
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Allogeneic hematopoietic stem cell transplant implantation rate
The proportion of the number of patients who achieved hematopoietic reconstitution to the total number of allogeneic hematopoietic stem cell transplantation patients in the same period.
Up to 100 days after Treatment
Time to neutrophil and platelet engraftment
The time for neutrophils and platelets to reach the implantation criteria after stem cell reinfusion
Up to 30 days after Treatment
Disease-feesurvival，DFS
The proportion of disease-free patients who survived to the total number of patients who transplanted allogeneic hematopoietic stem cells during the same period.
Up to 2 years after Treatment
Overall survival, OS
After transplantation until death from any cause.
Up to 2 years after Treatment
Participation Assistant
Eligibility Criteria

Eligible Ages
Child, Adult, Older Adult
Eligible Sexes
All

  • 1. Non-malignant blood and immune system diseases include: hereditary bone marrow failure, congenital immune deficiency, hemoglobinopathy and other non-malignant blood and immune system diseases,

    1. Confirmed hereditary bone marrow failure syndrome. Including: Fanconi anemia, congenital pure red cell aplastic anemia, congenital dyskeratosis, Scheux-Day syndrome, congenital neutropenia, various bone marrow failure related congenital thrombocytopenia and other unclassified congenital bone marrow exhaustion diseases;
    2. It meets the criteria of clinical manifestation, immune function and gene diagnosis of immune deficiency disease;
    3. Diagnosed with hemoglobinopathy and dependent on blood transfusions; serum ferritin levels are < 3000 μg/L, with cardiac and hepatic iron content indicating moderate or lower iron overload; documentation of iron chelation therapy (including prescriptions or invoices) for at least three months prior to screening is available; no hydroxyurea, ruxolitinib, decitabine, or cytarabine has been administered in the three months preceding enrollment. The spleen size must not extend beyond the umbilical horizontal line or the midline of the abdomen. Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is indicated, and suitable donors for related allo-HSCT are available.

  • 2. Serum total bilirubin ≤1.5 times the upper limit of normal value, serum Alanine aminotransferase (ALT) and Aspartate aminotransferase (AST) ≤ 3 times the upper limit of normal value range;

  • 3. Echocardiography showed Left ventricular ejection fraction (LVEF) >50%;

  • 4. Pulse oxygen saturation ≥92% (non-oxygen state);

  • 5. The estimated survival is more than 3 months;

  • 6. ECOG score 0-1;

  • 7. Abdominal B-ultrasonography and other examinations were performed to evaluate spleen size. Splenectomy should be evaluated before transplantation for patients with giant spleen;

  • 8. Women and men who are fertile must consent to the use of appropriate contraception before entering the study, during study participation, and for 6 months after transfusion (the safety of this therapy for the unborn child is not known, with unknown risks);

  • 9. Subjects who are willing to participate in the study are able to understand and have the ability to sign informed consent.

  • 1. People with a history of epilepsy or other central nervous system disorders;
  • 2. Epstein-Barr virus (EBV) DNA positive;
  • 3. People with a history of prolonged QT interval or serious heart disease;
  • 4. People with active hepatitis B or C virus;
  • 5. Tuberculosis, AIDS and other major infectious diseases;
  • 6. Sepsis, pulmonary infection, intestinal infection and other major organ infection and poor control, and/or hypersensitive C-reactive protein, procalcitonin significantly elevated;
  • 7. People who have previously received other clinical studies and gene therapy;
  • 8. Any situation that the investigator believes may increase the risk to the subject or interfere with the test results.
Zhejiang University logoZhejiang University1067 active studies to explore
Yake Biotechnology Ltd. logoYake Biotechnology Ltd.
Study Responsible Party
He Huang, Principal Investigator, Principal Investigator, First Affiliated Hospital of Zhejiang University
Study Central Contact
Contact: He Huang, MD, 0571-87233772, [email protected]
Contact: Yongxian Hu, MD, 0571-87233772, [email protected]
1 Study Locations in 1 Countries

Zhejiang

The first affiliated hospital of medical college of zhejiang university, Hangzhou, Zhejiang, 310003, China
He Huang, MD, Contact, 0571-87233772, [email protected]
Yongxian Hu, MD, Contact, 0571-87233772, [email protected]
Recruiting